Dr. Dy on the Use of Sotorasib in KRAS G12C–Mutated NSCLC

Video

Grace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.

Grace Dy, MD, medical oncology, Roswell Park Comprehensive Cancer Center, discusses the use of sotorasib (Lumakras) in patients with non–small cell lung cancer (NSCLC) with KRAS G12C mutations.

The phase 1/2 CodeBreak 100 trial (NCT03600883) investigated sotorasib in pretreated patients with KRAS G12C–mutated NSCLC.

At 2 years of follow-up, which included an additional 48 patients from a phase 1 cohort, the updated objective response rate was about 41%, which fell within the expected range based on initial data, Dy says. Additionally, the median progression-free survival was about 6 months, Dy explains.

The updated results also examined patients who achieved responses during the initial findings, Dy explains. The analysis showed that about 51% of initial responders remained in response for 12 months or longer, and the median duration of response in these patients was 12.3 months, Dy concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,